Walleye Trading
ACAD icon

Walleye Trading’s Acadia Pharmaceuticals ACAD Stock Holding History

Walleye Trading’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,100
Closed -$590K – 4047
2025
Q4 		$590K Buy
22,100
+1,800
+9% +$43K ﹤0.01% 2722
2025
Q3 		$433K Buy
+20,300
New +$480K ﹤0.01% 2838
2024
Q2 		– Sell
-4,100
Closed -$75.8K – 4188
2024
Q1 		$75.8K Buy
4,100
+1,300
+46% +$32.2K ﹤0.01% 3880
2023
Q4 		$87.7K Sell
2,800
-7,100
-72% -$170K ﹤0.01% 4194
2023
Q3 		$206K Buy
9,900
+9,500
+2,375% +$258K ﹤0.01% 3578
2023
Q2 		$9.58K Sell
400
-400
-50% -$8.89K ﹤0.01% 4258
2023
Q1 		$15.1K Sell
800
-4,500
-85% -$85.7K ﹤0.01% 4294
2022
Q4 		$84.4K Sell
5,300
-2,800
-35% -$43.8K ﹤0.01% 4050
2022
Q3 		$133K Sell
8,100
-9,700
-54% -$157K ﹤0.01% 3937
2022
Q2 		$251K Buy
17,800
+2,900
+19% +$54.1K ﹤0.01% 3517
2022
Q1 		$361K Buy
14,900
+11,200
+303% +$271K ﹤0.01% 3248
2021
Q4 		$86K Sell
3,700
-16,800
-82% -$338K ﹤0.01% 4454
2021
Q3 		$341K Buy
+20,500
New +$395K ﹤0.01% 3338
2020
Q1 		– Sell
-4,700
Closed -$201K – 3896
2019
Q4 		$201K Buy
4,700
+2,600
+124% +$113K ﹤0.01% 3155
2019
Q3 		$76K Buy
2,100
+200
+11% +$6.07K ﹤0.01% 3428
2019
Q2 		$51K Buy
+1,900
New +$48.5K ﹤0.01% 3527
2019
Q1 		– Sell
-1,300
Closed -$21K – 4111
2018
Q4 		$21K Buy
+1,300
New +$25.2K ﹤0.01% 4328
2017
Q3 		– Sell
-100
Closed -$3 – 4031
2017
Q2 		$3 Buy
+100
New +$2.98K ﹤0.01% 4368
2016
Q2 		– Sell
-7,600
Closed -$212K – 5249
2016
Q1 		$212K Buy
+7,600
New +$166K ﹤0.01% 2729

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Walleye Trading's ACAD Position: Q1 2026 in Review

Walleye Trading sold out of Acadia Pharmaceuticals (ACAD) in Q1 2026, closing a stake of 6,846 shares — an estimated $183K sold.

Walleye Trading first reported a position in ACAD in Q4 2015 and held it in 16 quarters. The position peaked at $683K in Q4 2021. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Walleye Trading reported no remaining Acadia Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Walleye Trading sold 6,846 Acadia Pharmaceuticals shares in Q1 2026, an estimated $183K.
  • Walleye Trading first reported a position in Acadia Pharmaceuticals in Q4 2015 and held it in 16 quarters.
  • Walleye Trading's Acadia Pharmaceuticals position peaked at $683K in Q4 2021.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.